HGF, IL-1α, and IL-27 Are Robust Biomarkers in Early Severity Stratification of COVID-19 Patients
Authors:
- Álvaro Tamayo-VelascoÁTÁlvaro Tamayo-Velasco
- Pedro Martínez-PazPMPedro Martínez-Paz
- María Jesús Peñarrubia-PonceMPMaría Jesús Peñarrubia-Ponce
- Ignacio de la FuenteIFIgnacio de la Fuente
- Sonia Pérez-GonzálezSPSonia Pérez-González
- Itziar FernándezIFItziar Fernández
- Carlos DueñasCDCarlos Dueñas
- Esther Gómez-SánchezEGEsther Gómez-Sánchez
- Mario Lorenzo-LópezMLMario Lorenzo-López
- Estefanía Gómez-PesqueraEGEstefanía Gómez-Pesquera
- María Heredia-RodríguezMHMaría Heredia-Rodríguez
- Irene Carnicero-FrutosICIrene Carnicero-Frutos
Open Access
- 8 May 2021
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (9) , 2017
Abstract
Pneumonia is the leading cause of hospital admission and mortality in coronavirus disease 2019 (COVID-19). We aimed to identify the cytokines responsible for lung damage and mortality. We prospectively recruited 108 COVID-19 patients between March and April 2020 and divided them into four groups according to the severity of respiratory symptoms. Twenty-eight healthy volunteers were used for normalization of the results. Multiple cytokines showed statistically significant differences between mild and critical patients. High HGF levels were associated with the critical group (OR = 3.51; p < 0.001; 95%CI = 1.95–6.33). Moreover, high IL-1α (OR = 1.36; p = 0.01; 95%CI = 1.07–1.73) and low IL-27 (OR = 0.58; p < 0.005; 95%CI = 0.39–0.85) greatly increased the risk of ending up in the severe group. This model was especially sensitive in order to predict critical status (AUC = 0.794; specificity = 69.74%; sensitivity = 81.25%). Furthermore, high levels of HGF and IL-1α showed significant results in the survival analysis (p = 0.033 and p = 0.011, respectively). HGF, IL-1α, and IL 27 at hospital admission were strongly associated with severe/critical COVID-19 patients and therefore are excellent predictors of bad prognosis. HGF and IL-1α were also mortality biomarkers.Keywords
All Related Versions
Funding Information
- Instituto de Salud Carlos III (COV20/00491)
This publication has 39 references indexed in Scilit:
- The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and ApplicationAnnals of Internal Medicine, 2020
- Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational studyThe Lancet Respiratory Medicine, 2020
- Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, ChinaClinical Infectious Diseases, 2020
- Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, ChinaIntensive Care Medicine, 2020
- [Characteristics of peripheral blood leukocyte differential counts in patients with COVID-19].2020
- A Novel Coronavirus from Patients with Pneumonia in China, 2019New England Journal of Medicine, 2020
- [Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia].2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- Coronavirus infections and immune responsesJournal of Medical Virology, 2020
- Macrophage Activation-Like Syndrome: A Distinct Entity Leading to Early Death in SepsisFrontiers in Immunology, 2019